Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/10/2009

s."

Operational Key Events:

  • Raised $31.0 million from a registered direct offering that yielded $29.0 million in cash, net of $2.0 million of offering costs

  • Elected Ginger D. Constantine, M.D. to the Company's Board of Directors

  • FDA appointed Arthritis Advisory Committee recommended marketing approval for KRYSTEXXA

  • Presented six abstracts (two oral presentations and four posters) about KRYSTEXXA at the European League Against Rheumatism (EULAR) 2009 Annual Congress addressing various aspects of treatment failure gout.

  • Received a complete response letter from the FDA on July 31, 2009 stating that the FDA cannot at this time approve the BLA for KRYSTEXXA as a treatment for chronic gout in patients refractory to conventional therapy. The complete response letter cited deficiencies with the CMC section of the BLA and also provided the current draft of the proposed labeling and further guidance regarding a Risk Evaluation and Mitigation Strategy (REMS). We expect to resubmit our BLA to the FDA in early 2010 to respond to the FDA's complete response letter.

  • Received notification from the FDA of a tentative meeting date scheduled for mid-September 2009 to discuss the complete response letter issued by the FDA in response to the "Type A" Meeting request filed by the Company.

Financial Results of Operations for the Three Months Ended June 30, 2009

Total revenues for the second quarter of 2009 were $0.7 million compared with $0.4 million for the second quarter of 2008, an increase of $0.3 million. The increase is primarily the result of higher product sales of oxandrolone, our authorized generic product that promotes weight gain f
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... PA (PRWEB) June 01, 2015 Note: ... new development in breast cancer prevention. , A phase ... suggests that postmenopausal women with ductal carcinoma in situ ... treatment and prevention. , The study (NSABP B-35/NRG Oncology) ... who completed the standard five-year treatment with tamoxifen to ...
(Date:6/1/2015)... IL (PRWEB) June 01, 2015 There’s never ... especially when it comes to non-emergency, minor illnesses. , As ... , 24/7 online access to medical care via the Internet. ... via smartphone, tablet or computer. , “Everyone is busy. We ... be a challenge, so we want to make it easier,” ...
(Date:6/1/2015)... Dallas, Texas (PRWEB) June 01, 2015 ... the brain health landscape on a global level. ... innovative realms, allowing Carrick Brain Centers to broaden their ... of healing. , Broadened horizons are accompanied by a ... June 1, 2015, Carrick Brain Centers will separate itself ...
(Date:6/1/2015)... NY (PRWEB) June 01, 2015 ... taking Sustamine® L-Alanyl-L-Glutamine inhibits signaling proteins that activate ... build-up after resistance exercise. 1 , The ... Acids, included 89 male Spraque-Dawley rats 2-3 months ... exercise, the rats were given either whey protein ...
(Date:6/1/2015)... 01, 2015 Strategic Radiology (SR) announced ... has joined forces with the SR coalition of progressive, ... this alignment, RRG will now have access to collective ... safety, clinical quality, and deployment of subspecialized radiology services. ... 22 member and affiliate US based radiology group practices. ...
Breaking Medicine News(10 mins):Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:Carrick Brain Centers announces separation from Dr. Frederick Carrick to reflect the broader scope of impact and growth as an organization. 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 2Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 3Health News:Rome Radiology Group Aligns with the Strategic Radiology® National Coalition 4
... SNM,s Molecular Imaging Center of Excellence kicked off ... scientific disciplinesincluding chemistry, engineering, physics, molecular biology, neurosciences ... molecular neuroimaging. "Molecular Imaging Symposium: Envisioning ... May 6-7 at the Natcher Auditorium of the ...
... ... & Celebrity Centre Nashville mobilized Volunteer Ministers to staff shelters at Lipscomb University and ... flooded downtown Nashville, causing thousands of residents and visitors to evacuate homes and hotels. ... Nashville (Vocus) ...
... among friends, family members and celebrities about their own struggles ... finds that more than a third of Americans polled believe ... attribute the change largely to openness by friends, family members ... 80 percent of those polled said that such openness on ...
... technique for reprogramming adult cells has given scientists an easier ... stem cells to study human disease from its earliest beginnings ... of disease and developing new therapies. But the ... different from embryonic stem cells in their ability to model ...
... LOUIS A residential summer weight-loss camp markedly improved ... of Pediatrics reports. A Saint Louis ... mass index (BMI), physical fitness and blood pressure. ... redirect the social environment to be successful," said Nadim ...
... ... founder of FDAImports.com, LLC has been in an ongoing, and sometimes heated ... 99-30, which authorized FDA to detain any milk-based products due to the ... efforts of those who challenged FDA on the issue produced fruit. FDA ...
Cached Medicine News:Health News:Envisioning the future of neuroscience 2Health News:Envisioning the future of neuroscience 3Health News:Church of Scientology Nashville Mobilizes Scientology Volunteer Ministers to Cope with Floods 2Health News:Same disease, different stem cell models 2Health News:Same disease, different stem cell models 3Health News:The biggest winners: Summer campers 2Health News:U.S. FDA Removes Many Chinese Candies From Import Alert 99-30 Based on Insufficient Evidence, According to FDAImports.com, LLC 2Health News:U.S. FDA Removes Many Chinese Candies From Import Alert 99-30 Based on Insufficient Evidence, According to FDAImports.com, LLC 3Health News:U.S. FDA Removes Many Chinese Candies From Import Alert 99-30 Based on Insufficient Evidence, According to FDAImports.com, LLC 4Health News:U.S. FDA Removes Many Chinese Candies From Import Alert 99-30 Based on Insufficient Evidence, According to FDAImports.com, LLC 5
(Date:6/1/2015)... LA JOLLA, Calif. , June 1, 2015 ... RGLS ), a biopharmaceutical company leading the discovery ... today that Kleanthis G. Xanthopoulos , Ph.D. ... and as a member of Regulus, Board of ... the biotechnology industry.  Paul Grint, M.D., who previously ...
(Date:6/1/2015)... 1, 2015  bioMérieux, a world leader in the ... invited to join the White House Forum on Antibiotic ... U.S. as a means to address antibiotic resistance. Over ... June 2, 2015, to discuss the possible ways to ... the emergence of antibiotic-resistant bacteria, and prevent the spread ...
(Date:6/1/2015)... Pa. , June 1, 2015 Select ... that MJ Acquisition Corporation, a joint venture that Select ... XII, L.P., has completed its previously announced acquisition of ... the new joint venture. About Select ... operator of specialty hospitals and outpatient rehabilitation clinics in ...
Breaking Medicine Technology:Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 2bioMerieux Honored to Participate in the White House Forum on Antibiotic Stewardship 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... Oct. 7 Sunridge International (OTC Bulletin Board: ... Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, ... by Beijing Vision World Trading Co. Ltd. (BVW), in ... patient research studies before gaining regulatory approval by China,s ...
... Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating the use of Nexavar® (sorafenib) tablets will be presented ... October 8-12, 2010 in Milan, Italy. "It,s ... its first indication, advanced kidney cancer, and since that time ...
Cached Medicine Technology:Sunridge Advances its PNT Glaucoma Treatment Throughout China 2Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress 2Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress 3Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress 4
... Povidone Iodine (PVP-I) Prep Sponge ... 10% Povidone Iodine, USP solution ... Triad Plus Povidone Iodine (PVP-I) ... with a 7.5% Povidone Iodine, ...
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
Medicine Products: